UNSPSC 51102902: Atovaquone/proguanil

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AP101. This VA Drug Class (AP101) classifies this compound as belonging to the group ANTIMALARIALS.

UNSPSC 51102902 Atovaquone/proguanil, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two most recent opportunities posted under this code involve pharmaceutical products — Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets through an Illinois Department of Public Health piggyback award, and Naloxone and drug deactivation systems through a Seminole County, Florida competitive bid — neither of which matches atovaquone/proguanil's actual therapeutic use as an antimalarial and antiprotozoal agent. The mismatch suggests either miscoding in state procurement systems or inconsistent application of the UNSPSC taxonomy by issuing bodies tagging pharmaceutical warehouse contracts and public health supply acquisitions.

State and local governments have posted pharmaceutical procurement activity under this code through health departments and county public health authorities. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC via IFB (Invitation for Bid) on August 28, 2026 for antibiotic tablets with 12-month initial term and two renewal options. Seminole County, Florida issued an IFB on June 30, 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through electronic submission, with a response deadline of July 26, 2023. Recent activity is concentrated in Florida and Illinois, with procurement occurring through state health departments and county public health divisions. Given the code's documented mismatch with current solicitations and the absence of genuine atovaquone/proguanil opportunities in the recent record, this code warrants close monitoring to confirm whether current pharmaceutical opportunities represent systematic miscoding or whether actual antimalarial procurement emerges under corrected category assignment.